Kymera Therapeutics paid its 5 named executives $23.6M in total in FY2025 (Dec).
Pay of each named executive
Brian Adams, J.D.Chief Legal Officer
| FY2025 (Dec) |
1 year
Noah Goodman, MBAChief Business Officer
| FY2025 (Dec) |
1 year
Jared Gollob, M.D.Chief Medical Officer
| FY2025 (Dec) | |||||||
| FY2024 (Dec) | |||||||
| FY2023 (Dec) | |||||||
| FY2022 (Dec) | Not disclosed | ||||||
| FY2021 (Dec) | Not disclosed |
5 years
Bruce Jacobs, CFA, MBAChief Financial Officer
| FY2025 (Dec) | |||||||
| FY2024 (Dec) | |||||||
| FY2023 (Dec) | |||||||
| FY2022 (Dec) | Not disclosed | ||||||
| FY2021 (Dec) | Not disclosed |
5 years
CEO pay against the pay peers
In FY2025 (Dec), the median CEO pay of the 9 peers with pay on file was $10.7M. The CEO of Kymera Therapeutics was paid $8.5M, 20% below the median.
- 1Scholar Rock Holding
- 2Viking Therapeutics
- 3Revolution Medicines
- 4Protagonist Therapeutics
- 5Immunovant
- 6IDEAYA Biosciences
- 7Kymera TherapeuticsThis company
- 8Vera Therapeutics
- 9Beam Therapeutics
- 10Denali Therapeutics
- 11ApogeeTherapeuticsNot disclosed
- 12ArcellxNot disclosed
- 13ArvinasNot disclosed
- 14Avidity BiosciencesNot disclosed
- 15BiohavenNot disclosed
- 16Dyne TherapeuticsNot disclosed
- 17ImmunityBioNot disclosed
- 18NuvalentNot disclosed
- 19VaxcyteNot disclosed
Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.